|
|
Volumn 346, Issue , 2013, Pages
|
|
FDA is to assess data linking type 2 diabetes drugs with pancreatitis.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
GLUCAGON LIKE PEPTIDE 1;
CHEMICALLY INDUCED DISORDER;
DRUG ANTAGONISM;
FACTUAL DATABASE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PANCREAS TUMOR;
PANCREATITIS;
PATHOPHYSIOLOGY;
PRECANCER;
RISK ASSESSMENT;
UNITED STATES;
DATABASES, FACTUAL;
DIABETES MELLITUS, TYPE 2;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
HYPOGLYCEMIC AGENTS;
PANCREATIC NEOPLASMS;
PANCREATITIS;
PRECANCEROUS CONDITIONS;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84877113938
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.f1808 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
